A Case of Acute Pericarditis and Hypereosinophilia After Dupilumab Initiation.

Tiffany Truong, Ani Shirvanian, Marcel Hariri, Roy Artal, Sherwin Hariri

Abstract readCase Reports

In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Tiffany TruongDepartment of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.

Ani ShirvanianDepartment of Allergy and Immunology, Cedars-Sinai Medical Center, Los Angeles, USA.

Marcel HaririDepartment of Allergy and Immunology, Rose and Alex Pilibos Armenian School, Los Angeles, USA.

Roy ArtalDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.

Sherwin HaririDepartment of Allergy and Immunology, Cedars-Sinai Medical Center, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dupilumab is a monoclonal antibody approved to treat multiple type 2 inflammatory conditions. Dupilumab-associated hypereosinophilia is a well-documented side effect and typically does not lead to clinical symptoms or pathologic findings. We report a 65-year-old man with asthma and nasal polyposis who presented with pleuritic chest pain after two doses of dupilumab. Our evaluation revealed peripheral hypereosinophilia and pericardial thickening consistent with pericarditis on cardiac MRI. The patient was treated with ibuprofen and colchicine, did not require corticosteroids, and dupilumab was discontinued. Subsequently, his eosinophil counts normalized, and his symptoms resolved. To our knowledge, this is the first published case of dupilumab-induced hypereosinophilia followed by isolated pericardial involvement.

Indexed as

acute pericarditisacute pericarditis after dupilumabdupilumabeosinophilic pericarditishypersensitivity pericarditis

Identifiers

PMID41994673

DOI10.7759/cureus.105073

PMCPMC13080952

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.